How could Amgen's successful trial results affect Eli Lilly and Company?
Amgen's Repatha success increases competitive pressure on Eli Lilly The announcement of the VESALIUS-CV trial results strengthens Amgen's position in the advanced cholesterol drug market. The trial showed that Repatha cut the combined risk of coronary heart disease death, heart attack, or ischemic stroke by 25% over a median of about 4.6 years. Furthermore, the health economic analysis found Repatha to be cost-effective for high-risk adults, coming in about 36% below the 2025 AHA and ACC benchmark of $120,000 per QALY. This favorable clinical and economic profile increases the competitive intensity for Eli Lilly and Company, a direct competitor in the advanced drug market.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- No new developments lately
How it reaches Eli Lilly and Company
-
Amgen announced results from the VESALIUS-CV trial, presenting a health economic analysis of its cholesterol drug Repatha. The analysis found Repatha to be cost-effective for high-risk adults who have never had a heart attack or stroke. This cost was approximately 36% below a benchmark used by the American College of Cardiology and American Heart Association. The analysis was led by the Duke Clinical Research Institute in collaboration with Mass General Brigham and Harvard.
The full event1independent outlet -
Amgen and Eli Lilly and Company are direct competitors in the advanced drug market, specializing in therapies like Lp(a) reduction. Amgen's favorable trial and cost-effectiveness results strengthen its market position, thereby increasing competitive pressure on Eli Lilly and Company's offerings.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American pharmaceutical company
Everything about Eli Lilly and Company
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Repatha cut the combined risk of coronary heart disease death, heart attack or ischemic stroke by 25% over a median of about 4.6 years.medicaldaily.com
- The drug was found to be about 36% below a benchmark used by the American College of Cardiology and American Heart Association.medicaldaily.com
- The 2025 AHA and ACC cost and value statement sets $120,000 per QALY as that threshold.medicaldaily.com
- Amgen sells Repatha through its AmgenNow direct-to-patient program at $239 a month.medicaldaily.com
Why it matters
The advanced drug market for cholesterol and cardiovascular risk is highly competitive, with both Amgen and Eli Lilly and Company specializing in complex therapies like Lp(a) reduction. A favorable clinical outcome, coupled with a strong cost-effectiveness ratio, allows a company to gain significant market traction and influence prescribing habits among high-risk patients.
This success puts pressure on competitors to demonstrate similar clinical efficacy and economic value for their own advanced treatments. The market relies heavily on these cost-effectiveness analyses, as they determine whether insurers and patients view a drug as worth its cost, which directly impacts revenue potential for all players in the space.
What we don't know yet
- How will Eli Lilly and Company adjust its strategy in response to Amgen's strong cost-effectiveness data?
- Will the full analysis of the VESALIUS-CV trial be published in a peer-reviewed journal?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- medicaldaily.comTuesday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.